Literature DB >> 18684363

MASCARA (Manejo del Síndrome Coronario Agudo. Registro Actualizado) study. General findings.

Ignacio Ferreira-González1, Gaietà Permanyer-Miralda, Jaume Marrugat, Magda Heras, José Cuñat, Emilia Civeira, Fernando Arós, Juan J Rodríguez, Pedro L Sánchez, Héctor Bueno.   

Abstract

INTRODUCTION AND
OBJECTIVES: To investigate the clinical characteristics and treatment of acute coronary syndromes (ACS), and to determine the effects of an early invasive strategy (EIS) in non-ST-elevation ACS (NSTEACS) and of primary percutaneous coronary intervention (PCI) in ST-elevation ACS (STEACS).
METHODS: Data were collected prospectively for 9 months during 2004-2005 from 50 hospitals, which were randomly selected according to the level of care provided. In addition, follow-up data on mortality and readmission for ACS were collected for 6 months. The adjusted effects of different reperfusion strategies were analyzed.
RESULTS: After checking data quality, the analysis included data from 32 hospitals, which covered 7923 coronary events (4431 [56%] STEACS, 3034 [38%] NSTEACS and 458 [6%] unclassified ACS) in 7251 patients. Compared with previous studies, the use of primary PCI in STEACS had increased markedly (from 10.7% to 36.8% of patients undergoing reperfusion), as had the use of EIS in NSTEACS (from 11.1% to 19.6%). Overall in-hospital mortality was 5.7% (95% confidence interval [CI], 5.1%-6.2%); for STEACS it was 7.6% (95% CI, 6.7%-8.7%), for NSTEACS 3.9% (95% CI, 3.3%-4.6%), and for unclassified ACS 8.8% (95% CI, 6.2%-12.2%). In the population as a whole, there was no association between prognosis (i.e., 6-month mortality) and EIS in NSTEACS (hazard ratio [HR]=0.94; 95% CI, 0.66-1.3) or between prognosis and primary PCI in STEACS (HR=1; 95% CI, 0.7-1.5). Findings for mortality and rehospitalization for ACS at 6 months were similar.
CONCLUSIONS: Data for 2004-2005 demonstrated a marked increase in the use of invasive procedures. However, the procedures employed were poorly matched to the patients' baseline risk.

Entities:  

Mesh:

Year:  2008        PMID: 18684363

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  8 in total

1.  Influence of comorbid conditions on one-year outcomes in non-ST-segment elevation acute coronary syndrome.

Authors:  Juan Sanchis; Julio Núñez; Vicente Bodí; Eduardo Núñez; Ana García-Alvarez; Clara Bonanad; Ander Regueiro; Xavier Bosch; Magda Heras; Joan Sala; Oscar Bielsa; Angel Llácer
Journal:  Mayo Clin Proc       Date:  2011-02-23       Impact factor: 7.616

2.  Secondary prevention strategies after an acute ST-segment elevation myocardial infarction in the AMI code era: beyond myocardial mechanical reperfusion.

Authors:  Núria Ribas; Cosme García-García; Oona Meroño; Lluís Recasens; Silvia Pérez-Fernández; Víctor Bazán; Neus Salvatella; Julio Martí-Almor; Jordi Bruguera; Roberto Elosua
Journal:  BMC Cardiovasc Disord       Date:  2017-02-07       Impact factor: 2.298

3.  Risk Assessment after ST-Segment Elevation Myocardial Infarction: Can Biomarkers Improve the Performance of Clinical Variables?

Authors:  Alvaro Garcia-Osuna; Jordi Sans-Rosello; Andreu Ferrero-Gregori; Aitor Alquezar-Arbe; Alessandro Sionis; Jordi Ordóñez-Llanos
Journal:  J Clin Med       Date:  2022-02-25       Impact factor: 4.241

4.  National Registry of Acute Coronary Syndrome in Paraguay (RENASCA-PY).

Authors:  Graciela González; Felipe Fernández; Domingo Ávalos; José Ortellado; Miguel Adorno; Javier Galeano; César Delmás; Guillermo Oviedo; Abdón Villamayor; Carmen Saldívar; Lucas Aquino; Manuel Castillo; Gilberto Machado; Silvio Silvero; Graciela Chaves; Nancy Gómez; Cristina Cáceres-Italiano; José Battilana; Gustavo Escalada; Federico Cabral; Édgar López; Gustavo Olmedo; Marcos Melgarejo; Luz Cabral; Óscar Paredes
Journal:  Arch Cardiol Mex       Date:  2022

5.  Risk factors and therapeutic coverage at 6 years in patients with previous myocardial infarction: the CASTUO study.

Authors:  Francisco Javier Félix-Redondo; Luis Lozano Mera; Luciano Consuegra-Sánchez; Fernando Giménez Sáez; Francisco Javier Garcipérez de Vargas; José María Castellano Vázquez; Daniel Fernández-Bergés
Journal:  Open Heart       Date:  2016-02-26

6.  Cost-effectiveness of a European ST-segment elevation myocardial infarction network: results from the Catalan Codi Infart network.

Authors:  Ander Regueiro; Julia Bosch; Victoria Martín-Yuste; Alba Rosas; Maria Teresa Faixedas; Joan Antoni Gómez-Hospital; Jaume Figueras; Antoni Curós; Angel Cequier; Javier Goicolea; Antonio Fernández-Ortiz; Carlos Macaya; Ricard Tresserras; Laura Pellisé; Manel Sabaté
Journal:  BMJ Open       Date:  2015-12-09       Impact factor: 2.692

7.  High adherence to therapy and low cardiac mortality and morbidity in patients after acute coronary syndrome systematically managed by office-based cardiologists in Germany: 1-year outcomes of the ProAcor Study.

Authors:  Franz Goss; Johannes Brachmann; Christian W Hamm; Winfried Haerer; Nicolaus Reifart; Benny Levenson
Journal:  Vasc Health Risk Manag       Date:  2017-04-06

8.  Benefit of primary percutaneous coronary interventions in the elderly with ST segment elevation myocardial infarction.

Authors:  Daniel Fernández-Bergés; Irene R Degano; Reyes Gonzalez Fernandez; Isaac Subirana; Joan Vila; Manuel Jiménez-Navarro; Silvia Perez-Fernandez; Mercé Roqué; Antoni Bayes-Genis; Francisco Fernandez-Aviles; Antonio Mayorga; Vicente Bertomeu-Gonzalez; Juan Sanchis; Marcos Rodríguez Esteban; Antonio Sanchez-Hidalgo; Esther Sanchez-Insa; Ane Elorriaga; Emad Abu Assi; Alberto Nuñez; Jose Manuel Garcia Ruiz; Pedro Morrondo Valdeolmillos; Daniel Bosch-Portell; Iñaki Lekuona; Andres Carrillo-Lopez; Alberto Zamora; Berta Vega-Hernandez; Javier Alameda Serrano; Catalina Rubert; Luis Ruiz-Valdepeñas; Laura Quintas; Luis Rodríguez-Padial; Jessica Vaquero; Luis Martinez Dolz; Jose A Barrabes; Pedro L Sanchez; Alessandro Sionis; Julio Martí-Almor; Roberto Elosua; Rosa-María Lidon; David Garcia-Dorado; Jaume Marrugat
Journal:  Open Heart       Date:  2020-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.